Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInventory AverageInvested CapitalMarket Capitalization

RedHill Biopharma (RDHL) EBITDA Margin: 2012-2023

Historic EBITDA Margin for RedHill Biopharma (RDHL) over the last 11 years, with Jun 2023 value amounting to 5,637.14%.

  • RedHill Biopharma's EBITDA Margin rose 592476.00% to 5,637.14% in Q2 2023 from the same period last year, while for Jun 2023 it was -148.01%, marking a year-over-year increase of 9419.00%. This contributed to the annual value of -174.38% for FY2024, which is 54062.00% down from last year.
  • As of Q2 2023, RedHill Biopharma's EBITDA Margin stood at 5,637.14%, which was up 503.81% from -1,395.97% recorded in Q1 2023.
  • RedHill Biopharma's EBITDA Margin's 5-year high stood at 5,637.14% during Q2 2023, with a 5-year trough of -1,395.97% in Q1 2023.
  • Over the past 3 years, RedHill Biopharma's median EBITDA Margin value was 105.05% (recorded in 2021), while the average stood at 279.30%.
  • Examining YoY changes over the last 5 years, RedHill Biopharma's EBITDA Margin showed a top increase of 592,476bps in 2023 and a maximum decrease of 155,263bps in 2023.
  • Quarterly analysis of 5 years shows RedHill Biopharma's EBITDA Margin stood at 739.87% in 2019, then crashed by 63,736bps to 102.51% in 2020, then plummeted by 87,781bps to -775.29% in 2021, then plummeted by 31,557bps to -1,090.87% in 2022, then spiked by 592,476bps to 5,637.14% in 2023.
  • Its EBITDA Margin was 5,637.14% in Q2 2023, compared to -1,395.97% in Q1 2023 and -1,090.87% in Q4 2022.